Search clinical trials for: ALGRX 3268

Total 67 results

AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.

Procedural Pain

United States
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.

Pain

United States
AlgoRx Pharmaceuticals

Completed

Study of ALGRX 3268 for Needlestick Pain in Children

Pain

United States
AlgoRx Pharmaceuticals

Completed

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

Neuroma

United States
AlgoRx Pharmaceuticals

Completed

ALGRX 4975 in the Treatment of Tennis Elbow

Tennis Elbow

Slovakia
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

Postoperative Pain

Former Serbia and Montenegro
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

Postoperative Pain

Denmark
AlgoRx Pharmaceuticals

Completed

ALGRX 4975 After Total Knee Replacement

Knee Injuries | Arthroplasty, Replacement, Knee

United States
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)

Completed

Clinical Trial of AVL-3288 in Schizophrenia Patients

Schizophrenia | Schizoaffective Disorder

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

Head and Neck Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Other Metastatic Solid Tumors

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Head and Neck Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Other Metastatic Solid Tumors

United States
Kinnate Biopharma

Active, not recruiting

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Intrahepatic Cholangiocarcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Korea, Republic of, Taiwan, China, Denmark, Spain
Shenzhen TargetRx, Inc.
The First Affiliated Hospital of Soochow University

Not yet recruiting

TGRX-326 Pharmacokinetic Mass Balance

Non Small Cell Lung Cancer
IGM Biosciences, Inc.

Terminated

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

COVID-19 | Healthy Volunteers

South Africa
Yale University

Terminated

FAAH Availability in Psychiatric Disorders: A PET Study

Post Traumatic Stress Disorder | Psychosis | Alcohol Use Disorder

United States
IGM Biosciences, Inc.

Terminated

Evaluation of IGM-6268 in Healthy Volunteers

Healthy Volunteers

United States
Dendreon

Completed

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Solid Tumors

United States
Shenzhen TargetRx, Inc.
Zhejiang Cancer Hospital; Sun Yat-sen University; Fujian Cancer Hospital; First... and other collaborators

Recruiting

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Active, not recruiting

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Bayer
Novartis

Completed

Inhalation Flow Rate-study

Bronchiectasis

Germany
Rigshospitalet, Denmark

Completed

Sensory Function After Wound Instillation of Capsaicin

Primary Hyperalgesia

Denmark
Celgene

Completed

Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants

Healthy Volunteers

Belgium
Baxalta now part of Shire

Completed

BAX 326 Pediatric Study

Hemophilia B

Russian Federation, Ukraine, India, Poland, Romania, United Kingdom
AbbVie

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, France, Japan, Puerto Rico, Spain, Taiwan
Janssen Research & Development, LLC

Completed

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Neoplasms | Colorectal Cancer | Advanced Solid Tumors | Non-small Cell Lung Cancer

France, United States
AbbVie

Terminated

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Universitat Internacional de Catalunya

Completed

Safety, Galenic Acceptability and Efficacy of GV-328 Lozenges in Children With Oral Aphthosis

Aphthous Stomatitis

Spain
AltruBio Inc.
ICON plc

Completed

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Healthy Volunteers

United States
AltruBio Inc.

Recruiting

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Ulcerative Colitis

United States, Canada
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
University of Colorado, Denver
National Institute of Mental Health (NIMH)

Terminated

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects (AVL3288)

Schizophrenia

United States
Baxalta now part of Shire

Completed

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Hemophilia B

Korea, Republic of
Centocor, Inc.

Completed

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

France, United Kingdom, Netherlands, Czech Republic
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Centocor, Inc.

Completed

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Lymphoma, Non-Hodgkin | Multiple Myeloma | Giant Lymph Node Hyperplasia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Centocor, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

Healthy

Belgium
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
University of Maryland, Baltimore

Withdrawn

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Cognitive Change
Jacobio Pharmaceuticals Co., Ltd.
AbbVie

Recruiting

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Northwestern University
National Cancer Institute (NCI)

Withdrawn

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Myelofibrosis | Thrombocytopenia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Sorrento Therapeutics, Inc.

Withdrawn

Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Solid Tumor, Adult | Refractory Cancer | Relapsed Solid Neoplasm
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Multicentric Castleman's Disease

United States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Belgium, Israel, India, Korea, Republic of, Netherlands, Singapore, Brazil, Russian Federation, New Zealand, Hungary, Norway, Australia, Egypt, Hong Kong, Malaysi...
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity

Melanoma

United States
Centocor, Inc.

Completed

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostatic Neoplasms

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Sciatica

United States

Search clinical trials for: ALGRX 3268

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations